Ftse Mib
33.285,03
0,17%
DAX
19.146,17
0,76%
S&P 500
5.954,94
0,64%
NASDAQ
18.967,51
0,01%
Bitcoin
98.033,45
3,90%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Argen X SE (ARGX) Argen X SE (ARGX) Notizie

ARGX

Argen X (ARGX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:ARGX
DataOraFonteTitoloSimboloCompagnia
20/11/202407:00GlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory MyopathiesEU:ARGXArgen X SE
11/11/202413:30GlobeNewswire Inc.argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in ChinaEU:ARGXArgen X SE
05/11/202407:00GlobeNewswire Inc.argenx to Participate at Upcoming Investor ConferencesEU:ARGXArgen X SE
31/10/202407:00GlobeNewswire Inc.argenx Reports Third Quarter 2024 Financial Results and Provides Business UpdateEU:ARGXArgen X SE
24/10/202407:00GlobeNewswire Inc.argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024EU:ARGXArgen X SE
15/10/202407:00GlobeNewswire Inc.argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific SessionsEU:ARGXArgen X SE
19/09/202407:00GlobeNewswire Inc.argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
28/08/202407:00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
25/07/202407:00GlobeNewswire Inc.argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business UpdateEU:ARGXArgen X SE
18/07/202407:00GlobeNewswire Inc.argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024EU:ARGXArgen X SE
16/07/202406:30GlobeNewswire Inc.argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in ChinaEU:ARGXArgen X SE
25/06/202422:30GlobeNewswire Inc.argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual MeetingEU:ARGXArgen X SE
21/06/202422:50GlobeNewswire Inc.argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
17/06/202407:00GlobeNewswire Inc.argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024EU:ARGXArgen X SE
04/06/202407:00GlobeNewswire Inc.argenx to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceEU:ARGXArgen X SE
09/05/202407:00GlobeNewswire Inc.argenx Reports First Quarter 2024 Financial Results and Provides Business UpdateEU:ARGXArgen X SE
07/05/202423:30GlobeNewswire Inc.argenx announces results of Annual General Meeting of ShareholdersEU:ARGXArgen X SE
07/05/202407:00GlobeNewswire Inc.argenx to Present at BofA Securities 2024 Health Care ConferenceEU:ARGXArgen X SE
02/05/202407:00GlobeNewswire Inc.argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024EU:ARGXArgen X SE
16/04/202407:00GlobeNewswire Inc.argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseEU:ARGXArgen X SE
27/03/202407:00GlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s DiseaseEU:ARGXArgen X SE
26/03/202421:00GlobeNewswire Inc.argenx Announces Annual General Meeting of Shareholders on May 7, 2024EU:ARGXArgen X SE
26/03/202407:00GlobeNewswire Inc.argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaEU:ARGXArgen X SE
07/03/202422:01GlobeNewswire Inc.argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual MeetingEU:ARGXArgen X SE
29/02/202407:00GlobeNewswire Inc.argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateEU:ARGXArgen X SE
22/02/202407:00GlobeNewswire Inc.argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024EU:ARGXArgen X SE
20/02/202407:00GlobeNewswire Inc.argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
18/01/202407:00GlobeNewswire Inc.argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia GravisEU:ARGXArgen X SE
08/01/202407:00GlobeNewswire Inc.argenx Highlights 2024 Strategic PrioritiesEU:ARGXArgen X SE
02/01/202407:00GlobeNewswire Inc.argenx to Present at 42nd Annual J.P. Morgan Healthcare ConferenceEU:ARGXArgen X SE
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:ARGX

La tua Cronologia

LSE
FIN
Finseta
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network